CardioSignal by Precordior

CardioSignal by Precordior is a health technology company based in Turku, Finland, and Palo Alto, California, that develops a mobile application utilizing smartphone motion sensors to detect cardiovascular conditions such as atrial fibrillation. Operating as a CE-marked class IIa medical device available in over 15 countries, the platform analyzes chest-placed gyrocardiography measurements in a secure cloud environment to provide immediate diagnostic results. The organization employs more than 30 people and has raised $23 million in total funding, including a $10 million Series A round led by DigiTx Partners with participation from Maki.vc. The company provides its remote monitoring technology to primary care physicians and has established strategic partnerships with major pharmaceutical and diagnostic corporations, including Novartis, Boehringer Ingelheim, and Roche Diagnostics. CardioSignal by Precordior was founded in 2016 by Juuso Blomster, Tuomas Valtonen, and Lasse Leppäkorpi.

High-Level Overview

CardioSignal, developed by Precordior, is a medical-grade smartphone app that detects atrial fibrillation (AFib) using gyrocardiography to analyze chest micro-motions via a phone's built-in sensors—no additional hardware needed. Users simply lie down, place the phone on their chest for one minute, and receive instant results with 95-96% accuracy.[1][2][4][6] It serves healthcare providers, primary care doctors, remote patient monitoring programs, and at-risk populations, solving the problem of late heart disease detection amid cardiology bottlenecks in hospitals by enabling scalable, low-cost screening for AFib, with upcoming expansions to heart failure (HF) and coronary artery disease (CAD).[1][2][3][5] Precordior, founded in 2016 in Turku, Finland, has raised $12.19M, holds 24 granted patents (plus 30+ pending), and achieved CE IIa certification in Europe while entering the US market in 2023 via FDA collaborations and partnerships like Mayo Clinic.[1][2][3][4]

The company shows strong growth momentum, including a $10M funding round in 2021 from investors like Maki.vc, wins like the American Heart Association grant, and board additions such as Ursula Burns (ex-Xerox CEO).[3][4] Projections from 2021 aimed for 1.27M daily users and €85M revenue by 2025 across EU, US, and China, driven by B2B sales to pharma (e.g., Roche, Novartis trials) and healthcare firms.[5]

Origin Story

Precordior spun out from the University of Turku in Finland in 2016 as an academic venture, building on over a decade of research in gyrocardiography—a technique using smartphone accelerometers and gyroscopes to measure heart-induced chest vibrations.[1][3][4][6] The idea emerged from cardiologists and technologists addressing unmet needs in early cardiac detection, starting with AFib, which causes millions of deaths yearly due to undetected cases.[5][6] Key figures include CEO Juuso Blomster, a cardiologist leading product vision.[4]

Early traction came from clinical validation: the V1 AFib app was proven effective, securing 19 patents initially (now 24+), EU Seal of Excellence, and CE IIa approval.[1][2][5][6] Pivotal moments include 2021's $10M funding, 2022 US entry announcements with AHA grant and Mayo Clinic acceptance, and 2023 FDA-aligned launches for remote care.[3][4]

Core Differentiators

• Hardware-Free Precision: Uses only smartphone sensors for 95-96% AFib detection accuracy, validated in clinical studies with 20+ peer-reviewed papers; expands to HF/CAD without wearables.[1][2][4][6]
• Speed and Simplicity: One-minute test delivers instant cloud-analyzed results, ideal for primary care, home monitoring, or population health programs—reducing hospital burdens.[1][3][5][6]
• Regulatory and IP Strength: CE IIa certified (ISO 13485/27001 compliant), 24 granted patents (30+ pending) on cardiac motion tech, with FDA progress for US remote care.[2][3][6]
• Proven Scalability: B2B2C model with pharma trials (Roche, Novartis), academic collaborations, and US ecosystem ties (Mayo, AHA, Ursula Burns on board).[3][4][5]

Role in the Broader Tech Landscape

CardioSignal rides the digital health and remote monitoring wave, accelerated by post-COVID demand for non-invasive, at-home diagnostics amid 300M+ EU and 1B global at-risk users for €4.2B TAM.[3][5][6] Timing aligns with smartphone ubiquity, AI-driven biomarker analysis, and cardiology overload—80% of CVD deaths from undetected heart attacks/strokes make early, scalable tools critical.[5] Market forces like aging populations, pharma's precision medicine push, and regulatory nods (FDA, CE) favor it, positioning Precordior to democratize cardiac care for underserved groups via population screening and point-of-care.[3][5]

It influences the ecosystem by pioneering gyrocardiography, inspiring sensor-based medtech, and fostering university-hospital trials that validate multi-disease detection under one app—potentially slashing costs versus ECGs or imaging.[1][4][6]

Quick Take & Future Outlook

CardioSignal is poised to disrupt cardiac diagnostics by bundling AFib, HF, and CAD into a single smartphone platform, with US launches expanding from Europe's CE base to capture pharma contracts and population health deals. Near-term: FDA-cleared remote solutions by 2026, leveraging 2023 momentum for broader adoption.[3] Shaping trends include AI-enhanced sensors, telehealth integration, and global equity in heart care, evolving Precordior's influence toward a full cardiac suite leader—scaling from $12M raised to projected €85M revenue while saving lives through everyday tech.[1][5] This ties back to its core: turning smartphones into lifesaving tools for the world's top killer.